Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers

10.1056/NEJMra1703413

10.1056/NEJMoa040938

10.1126/science.1099314

10.1016/S1470-2045(16)30146-2

10.1056/NEJMoa1006448

10.1200/JCO.2010.31.8923

10.5858/arpa.2012-0720-OA

10.1093/jnci/djp280

10.1073/pnas.0712345105

10.1056/NEJMoa1616288

10.1038/modpathol.2015.86

10.1038/bjc.2014.210

10.1158/1535-7163.MCT-11-0692

10.1158/0008-5472.CAN-04-2818

10.1093/jnci/dji055

10.7554/eLife.06907

10.1016/S1470-2045(15)00246-6

10.1097/JTO.0000000000000130

10.1093/ajcp/aqw043

10.1309/AJCP85ATMJOZOUDJ

Belchis DA, Tseng LH, Gniadek T, et al. Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.Oncotarget. 2016; 7 (29): 45237– 45248.

10.1309/AJCPMWGWGO34EGOD

10.5858/arpa.2013-0649-OA

10.1097/PDM.0000000000000029

Illei1 PB, Belchis D, Tseng LH, et al . Clinical mutational profiling of 1006 lung cancers by next generation sequencing.Oncotarget. 2017; 8 (57): 96684– 96696.

10.1016/S0092-8674(04)00215-6

10.1038/onc.2008.71

10.1158/1078-0432.CCR-13-0318

10.4132/jptm.2016.03.09

10.1200/JCO.2005.02.857

Gumerlock PH, Holland WS, Chen H, et al. Mutational analysis of K-RAS and EGFR implicates KRAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib.Proc Am Soc Clin Oncol. 2005; 23 (suppl 623s): abstract 7008.

10.1158/1078-0432.CCR-05-2845

10.1200/JCO.2007.14.8924

Benesova L, Minarik M, Jancarikova D, Belsanova B, Pesek M. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.Anticancer Res. 2010; 30 (5): 1667– 1671.

10.1038/bjc.2014.401

10.1097/MD.0000000000000296

10.1016/j.cllc.2015.11.004

10.1007/s00280-016-2969-y

10.3892/ol.2014.2169

10.1158/1078-0432.CCR-12-3173

10.1038/sj.onc.1210103

10.1038/ng.115

10.1371/journal.pone.0088291

10.1097/JTO.0000000000000516

10.1172/JCI28656

Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Sci Transl Med. 2011; 3 (75): 75ra26.

10.1097/JTO.0000000000000671

Hu W, Liu Y, Chen J. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.Oncotarget. 2017; 8 (15): 25046– 25054.

10.1200/JCO.2011.38.3224

10.1309/AJCP50WEZHWIFCIV